Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Lazard: Q2 Earnings Insights

  Lazard (NYSE:LAZ) reported its Q2 earnings results on Thursday, July 28, 2022 at 06:49 AM. Here's what investors need to know about the announcement. Earnings Lazard beat estimated earnings by 6.98%, reporting an EPS of $0.92 versus an estimate of $0.86.
byBenzinga Insights
July 28, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

 

Lazard (NYSE:LAZ) reported its Q2 earnings results on Thursday, July 28, 2022 at 06:49 AM.

Here’s what investors need to know about the announcement.

Earnings

Lazard beat estimated earnings by 6.98%, reporting an EPS of $0.92 versus an estimate of $0.86.

Revenue was down $145.53 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.18 which was followed by a 4.04% drop in the share price the next day.

Here’s a look at Lazard’s past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate 0.87 1.44 0.95 0.88
EPS Actual 1.05 1.92 0.98 1.28
Revenue Estimate 673.91M 858.32M 715.32M 652.31M
Revenue Actual 698.63M 967.95M 701.64M 821.45M

To track all earnings releases for Lazard visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

EXCLUSIVE: Fifteen New F1 Hybrid Cannabis Strains To Hit Shelves In US For 4/20 Under New Partnership

By Jelena Martinovic
April 10, 8:30 AM
California-based I Love Growing Marijuana (ILGM), announced on Tuesday an exclusive new partnership with cannabis genetics and breeding company, Phylos Bioscience, that brings 15 new F1 hybrid strains to home growers across legal markets nationwide. ILGM is launching half the collection of strains that are "crafted for potency, flavor, and diversity" on its website just in time for marijuana culture's high holiday on 4/20. In doing so, the company is leveraging Phylos Bioscience's cutting-edge technology and extensive genetic library, which Benzinga has learned exclusively. Ernst Rustenhoven, CEO of ILGM, commented on the new partnership. "ILGM caters to a customer base of novice and veteran home growers on the hunt for increasingly unique strains of superior genetics, and we have been seeking an innovative partner to help elevate and diversify our product offerings," Rustenhoven said. "In forging a relationship with Phylos, we are taking our seed catalog to the next level with a highly curated selection of sought-after F1 hybrid strains."

OGI

Read More

Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen And Safety Findings For ACU193 In Early Alzheimer’s Disease At The 16th Annual Clinical Trials On Alzheimer’s Disease

By Benzinga Newsdesk
October 27, 9:29 AM
- Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to inform dose selection, plus further analyses of dose-related amyloid

ABOS